New Delhi: India observed 3,832 new leprosy cases among children last year. According to the National Leprosy Eradication Programme’s Annual Report for the year 2025-26, published by the Central Leprosy Division of the Ministry of Health and Family Welfare, the observed cases nearly double the 2000-case target for the year. Among these 3,832 cases, 37 were diagnosed with Grade-2 Disability (G2D) at the time of detection – visible, irreversible damage to nerves, eyes, hands, or feet had already occurred before the disease was identified. These cases alone represent nearly half of the world’s total of 8,344 new child leprosy cases.Notably, cases among children below 15 years of age are considered an indicator of recent transmission by the World Health Organization (WHO). Disability among newly detected child cases signals both delayed detection and ongoing transmission. India also reported the world’s highest number of newly detected child leprosy cases in the WHO’s 2025 global update, which corresponds to India’s April 2025 to March 2026 reporting period.Simultaneously, India also reported 91,783 cases, constituting the world’s largest number of new leprosy cases across all age groups. This was far higher than the countries next, with Brazil reporting 22,901 new cases and Indonesia 16,292. Together, the three countries accounted for 78.3% of all new cases reported globally. The WHO’s Weekly Epidemiological Record for September 18, 2026 puts the global total at 167,356 new cases in 2025, which is 3.1% lower than in 2024. India’s cases account for more than half of all cases in the South-East Asia Region, which in turn carries 60% of the global burden. The 2027 goalIndia is working towards the National Strategic Plan and Roadmap for Leprosy 2023-2027, which sets the goal of interrupting transmission at the district level by 2027. The NLEP’s own programme objectives include zero Grade-2 Disability among new child cases. It has set a target of 1,000 child cases and a national G2D rate of 0.5 per million for 2026-27. The actual G2D rate recorded for 2025-26 was 1.34 per million population which is well above both the NLEP target of less than one case per million and the roadmap’s (2026-27) projection. A total of 1,945 patients across all age groups had Grade-2 Disability at diagnosis, accounting for 2.12% of all newly detected cases. A total 148 districts across 27 states and Union territories were provisionally identified in 2025-26 as having reached ‘Interruption of Transmission’ based on routine programme reporting. As of March 31, 2026, the Union health ministry identified 31 of 36 states and UTs, and 654 of 768 districts (85.15%), had achieved the elimination threshold below one case per 10,000 population. However, five states and one Union territory remain above this threshold – Chhattisgarh, Jharkhand, Maharashtra, Odisha and Chandigarh.The child caseload also has been detected lower than a decade ago, recording 11,365 children with leprosy in 2014-15, a figure that fell gradually to 7,859 in 2019-20. Numbers dropped sharply during the COVID-19 period to 3,753 in 2020-21, before rising to 4,107 in 2021-22, then falling again to 2,363 in 2022-23 and 2,335 in 2023-24. The 2025-26 figure of 3,832 represents a renewed rise. The NLEP notes that changes in reported case numbers also reflect the intensity and reach of case detection, making it difficult to read the trend as a direct measure of transmission alone.Globally, per the WHO, 284 new child cases had Grade-2 Disability in 2025, up from 256 the previous year, which is a signal that the problem of late detection among children is not confined to India alone, though India accounts for a significant share of that figure. Detection campaignThe primary strategy of the NLEP for finding hidden cases is the Leprosy Case Detection Campaign (LCDC). It is a house-to-house survey conducted in high-endemic districts by teams of trained volunteers. In 2025-26, LCDCs were conducted in 458 districts, screening 74.76 crore people out of an eligible 82 crore. Through these campaigns, 24,367 new cases were confirmed. The report also highlights that in 2025-26, 1.11 million ASHAs screened 59.43 crore people, referring to 39.46 lakh suspects. Of these referrals, 48,027 were confirmed as leprosy cases, accounting for 52.32% of all new cases detected during the year. Beyond this, the programme conducted Focused Leprosy Campaigns in localities where a Grade-2 Disability case was found, designating these as hotspots requiring house-to-house surveys of surrounding households. Dr. Kabir Sardana, Professor and Head of Dermatology at ABVIMS-Dr. RML Hospital in Delhi, attributed the continuing child caseload to gaps in detection. “Data points to the fact that there is poor detection, which is why we are seeing more children with leprosy,” as quoted by The Hindu. Leprosy is a chronic bacterial infection, affecting the skin and peripheral nerves. It is mainly transmitted through prolonged, close contact with an untreated person and can be cured with multidrug therapy, a combination of antibiotics provided free through public-health programmes. Children and household contacts are particularly important for surveillance, as a new case in a child may suggest recent or ongoing transmission within a community. However, such a case alone cannot determine when or where the infection was acquired. The disease has a long incubation period, averaging around five years but sometimes lasting considerably longer, which makes identifying and interrupting transmission difficult.The report noted that 16 states had notified leprosy as a notifiable disease under their respective health regulations, which the NLEP says is a step that will strengthen surveillance and accountability. The NLEP also introduced the Pharmacovigilance Programme of India for monitoring adverse drug reactions from leprosy treatment, with training completed in Haryana, Delhi and Uttar Pradesh. The Drug and Vaccine Distribution Management System has been integrated for drug logistics management. Moreover, a Special Monitoring Framework has been developed for 121 high-priority districts in 14 states. The NLEP’s digital system, Nikusth 2.0, has recorded over 2.60 lakh patient entries since its relaunch in January 2023, tracking individual cases, treatment compliance, relapses, and contact tracing.